Results 71 to 80 of about 1,389,538 (204)

Real‐World Status of Augmentation Therapy With Atypical Antipsychotics in Major Depressive Disorder: A Claims Database Study

open access: yesNeuropsychopharmacology Reports, Volume 46, Issue 4, December 2026.
Using real‐world data, AAP augmentation patterns were evaluated in patients with MDD initially treated with antidepressant monotherapy. AAP augmentation therapy was initiated after a relatively long interval. Although only a small proportion of patients received this therapy, nearly half showed claims‐defined continuation for more than 6 months ...
Hikaru Hori   +8 more
wiley   +1 more source

Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods

open access: yesMolecules, 2018
The neuropeptides, orexin A and orexin B (also known as hypocretins), are produced in hypothalamic neurons and belong to ligands for orphan G protein-coupled receptors.
Jana Janockova   +12 more
doaj   +1 more source

Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.

open access: yes, 2020
INTRODUCTION The last two decades have witnessed a rapid increase in the knowledge about the role of the orexin system, particularly in the regulation of wakefulness and arousal.
Vaillant C   +4 more
core   +1 more source

UK Medical Cannabis Registry: A Two‐Year Prospective Observational Cohort Study of Clinical Outcomes in Insomnia

open access: yesNeuropsychopharmacology Reports, Volume 46, Issue 4, December 2026.
Insomnia affects around one in ten adults. In this 2‐year UK Medical Cannabis Registry cohort study of 211 adults with insomnia, treatment with cannabis‐based medicinal products was associated with a sustained improvement in self‐reported sleep quality across 24 months.
Aran Koye   +7 more
wiley   +1 more source

Functional selectivity and kinetic features of orexin receptor antagonists

open access: yes, 2016
© 2016 Sui ChenOrexin receptor antagonists are under development for the treatment of insomnia and a number of other diseases. However, the medium to high throughput screening procedures used to discover or characterize orexin receptor antagonists (and ...
Chen, Sui
core   +1 more source

The Effects of Serotonin Receptor Antagonists on Contraction and Relaxation Responses Induced by Electrical Stimulation in the Rat Small Intestine [PDF]

open access: yes, 2014
Background: The main source of 5-HT in body is in enterchromafin cells of intestine, different studies mentioned different roles for endogenous 5-HT and receptors involved and it is not clearified the mechanism of action of endogenous 5-HT. Objectives:
Javid, Farideh A.   +2 more
core   +4 more sources

Locus coeruleus microstructural integrity and sleep disruption in the context of Alzheimer's disease pathology

open access: yesAlzheimer's &Dementia, Volume 22, Issue 11, November 2026.
Abstract INTRODUCTION The locus coeruleus (LC) is among the first sites of tau pathology in Alzheimer's disease (AD) and plays a key role in sleep–wake regulation. However, evidence linking LC integrity to objective sleep measures in the context of emerging AD pathology remains limited.
Maxime Van Egroo   +10 more
wiley   +1 more source

Therapeutic Prospects of Ketamine for Cataplexy in Narcolepsy Type 1: Evidence from a Human Case and a Murine Model

open access: yesAnnals of Neurology, Volume 100, Issue 5, Page 1023-1027, November 2026.
Narcolepsy type 1 is characterized by cataplexy, for which current treatments targeting monoaminergic, histaminergic, and GABAergic pathways may be ineffective or poorly tolerated. We report the case of a 34‐year‐old man with narcolepsy type 1, intolerant to standard therapies, who experienced marked and sustained cataplexy reduction with morning ...
Francois Ricordeau   +8 more
wiley   +1 more source

Efficacy of High‐Frequency Transcranial Magnetic Stimulation Therapy for Depression With Insomnia Symptoms: A Systematic Review and Meta‐Analysis Based on Randomized Controlled Trials

open access: yesBrain and Behavior, Volume 16, Issue 11, November 2026.
It summarizes the key findings: improves sleep quality (SMD0.97) and depressive symptoms(SMD0.61) in depression‐related insomia ABSTRACT Background This meta‐analysis evaluated the efficacy of high‐frequency repetitive transcranial magnetic stimulation (HF‐rTMS) targeting the left dorsolateral prefrontal cortex (DLPFC) in patients with comorbid ...
Wenqing Yang   +5 more
wiley   +1 more source

Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? [PDF]

open access: yes, 2014
Addiction is a chronic relapsing disorder which presents a significant global health burden and unmet medical need. The orexin/hypocretin system is an attractive potential therapeutic target as demonstrated by the successful clinical trials of antagonist
Brown, RM   +1 more
core   +3 more sources

Home - About - Disclaimer - Privacy